Median Technologies stock analysis
Want to see FR:ALMDT full AI Analyst Report?
Median Technologies (ALMDT) Stock Price & Analysis
ALMDT Stock Chart & Stats
- Day’s Range
- EUR 3.80 - EUR 3.96
- 52-Week Range
- EUR 2.75 - EUR 7.27
- Previous Close
- EUR 3.90
- Volume
- N/A
- Average Volume (3M)
- 150.56K
- Market Cap
- EUR 191.14M
- Enterprise Value
- EUR 200.68M
- Total Cash (Recent Filing)
- EUR 60.83M
- Total Debt (Recent Filing)
- EUR 26.12M
- Price to Earnings (P/E)
- ―
- Beta
- 0.92
- Next Earnings
- Apr 29, 2027 (Est.)
- EPS Estimate
- N/A
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Revenue Growth
The acceleration in reported revenue growth indicates that Median is expanding its commercial activity despite substantial profitability challenges. If this trajectory persists, greater scale could improve operating leverage, support investment in its imaging platform, and strengthen its position in oncology-focused clinical research.
Oncology Imaging Specialization
Median’s focused expertise in oncology imaging and artificial intelligence gives it a clearly defined role in cancer detection, assessment, and pharmaceutical development. This specialization can support durable customer relevance as clinical trials and healthcare systems increasingly use quantitative image analysis.
Multiple Revenue Channels
The business model reaches both biopharmaceutical customers and healthcare providers through imaging services, software, and AI products. This creates several potential routes for monetizing the company’s technology and reduces reliance on a single use case as products and contracts develop.
Bears Say
Persistent Losses
Persistent and exceptionally deep losses show that revenue growth has not yet translated into an economically sustainable business. Continued losses can restrict reinvestment, weaken negotiating flexibility, and make future performance dependent on achieving substantial improvements in pricing, costs, or operating scale.
Negative Operating Cash Flow
Repeated operating cash outflows indicate that the company is not currently funding its operations through internally generated cash. Ongoing burn reduces financial resilience and may require external funding or balance-sheet capacity, limiting the resources available for product development and commercial expansion.
Negative Equity Base
A negative equity position reflects the cumulative effect of losses and leaves the company with a weak capital base. This reduces financial flexibility, makes leverage harder to absorb, and increases the importance of successful operations or additional funding to support the business over the medium term.
Median Technologies News
ALMDT FAQ
What was Median Technologies’s price range in the past 12 months?
What is Median Technologies’s market cap?
When is Median Technologies’s upcoming earnings report date?
How were Median Technologies’s earnings last quarter?
Is Median Technologies overvalued?
Does Median Technologies pay dividends?
What is Median Technologies’s EPS estimate?
How many shares outstanding does Median Technologies have?
What happened to Median Technologies’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Median Technologies?
What is the TipRanks Smart Score and how is it calculated?
Company Description
Median Technologies
Headquartered in Valbonne, France, Median Technologies S.A. was established in 2002. This company specializes in developing and commercializing advanced software and platforms designed for medical image analysis. Its reach extends globally, serving markets in France, the United States, Canada, the United Kingdom, China, and beyond. Among its key offerings is iBiops, an innovative, AI-powered software classified as a medical device. This solution comprehensively integrates and optimizes the entire medical imaging workflow. Additionally, Median Technologies provides iSee, a service dedicated to image analysis specifically for clinical trials. Furthermore, the company delivers extensive imaging contract research organization (CRO) services. These encompass a wide range of activities, from study initiation and the management of both image and clinical data, to scientific advisory, independent reviews, image data processing, site support, and final study close-out. Solidifying its commitment to research, Median Technologies maintains a collaborative agreement with the University of California.
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Fredrik Brag
- Employees
- 200
- Website
- www.mediantechnologies.com
- Address
- 1800, Route des CrEtes, Valbonne, PAC, 06560, FR
Median Technologies (ALMDT) Earnings & Revenues
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 10 | 6 | 6 |
| Technical Analysis | 3 | 6 | 1 |
| Moving Averages | 7 | 0 | 5 |









